[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601835":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":19,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BsAbs-treatment group","EXPERIMENTAL","Patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration will receive radiation combined with a BCMA\u002FCD3 bispecific antibody (CM336)",[13],"Drug: BCMA\u002FCD3 bispecific antibody (CM336)",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","BCMA\u002FCD3 bispecific antibody (CM336)",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Gang An, MD","CONTACT","13502181109","angang@ihcams.ac.cn",[27],{"facility":28,"status":29,"city":30,"state":19,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences","RECRUITING","Tianjin","300020","China","CN",{"type":35,"coordinates":36},"Point",[37,38],117.17667,39.14222,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":19,"email":25},"Gang An, PhD&MD","008613502181109",{"type":45,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100601835","phase-2-radiation-combined-with-bcmacd3-bispecific-antibody-therapy-for-solitary-bone-plasmacytoma-with-mild-bone-marrow-infiltration-100601835",false,"NCT07115667","Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","A Prospective Single-Arm Clinical Trial of Radiation Combined With BCMA\u002FCD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration","Inclusion Criteria:\n\n* ≥18 years old\n* Histologically confirmed SBP with \\\u003C10% clonal plasma cells in marrow\n* ECOG ≤ 2\n* No prior anti-myeloma therapy. Previous local radiotherapy for SBP is not an exclusion criterion.\n* Meets laboratory and imaging criteria\n\nExclusion Criteria:\n\n1. Patients who have previously received anti-plasma cell therapy, including melphalan, cyclophosphamide, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, or chimeric antigen receptor T-cell (CAR-T) therapy.\n2. Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.","ALL","18 Years","78 Years",{"count":57,"type":58},21,"ESTIMATED","INTERVENTIONAL",[61],"PHASE2","This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA\u002FCD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.",[64,65,66],"Solitary Bone Plasmacytoma","Plasmacytoma of Bone","Plasma Cell Disorders",[68,69],"solitary bone plasmacytoma","BCMA\u002FCD3 bispecific antibody","2025-09-05",{"date":72,"type":73},"2025-09-08","ACTUAL",{"date":75,"type":73},"2025-08-25",{"date":77,"type":58},"2027-12-01",{"name":5,"class":6},1]